The ANXA3 Polyclonal Antibody (CAB12379) is a valuable tool for researchers studying ANXA3, a protein involved in various cellular processes including inflammation, cell growth, and apoptosis. This antibody, produced in rabbits, is specifically reactive with human samples and is validated for use in Western blot applications. It binds to the ANXA3 protein, allowing for the detection and analysis of ANXA3 in different cell types, making it suitable for studies in cancer research and cell biology.
ANXA3, also known as Annexin A3, is a member of the annexin family of calcium-binding proteins that play key roles in membrane-related events. Its involvement in inflammation and cell growth makes it a potential target for research into diseases such as cancer and inflammatory disorders. Understanding the function of ANXA3 is essential for developing therapies that target this protein and its associated pathways.
Product Name:
ANXA3 Rabbit Polyclonal Antibody
SKU:
CAB12379
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Rat
Immunogen:
Recombinant fusion protein containing a sequence corresponding to amino acids 1-323 of human ANXA3 (NP_005130.1).
This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. This protein functions in the inhibition of phopholipase A2 and cleavage of inositol 1,2-cyclic phosphate to form inositol 1-phosphate. This protein may also play a role in anti-coagulation.
Purification Method:
Affinity purification
Gene ID:
306
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3.
Western blot analysis of various lysates using ANXA3 Rabbit pAb (CAB12379) at 1:3000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25μg per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 1s.
